As with other anti-platelet agents, Clopidogrel should be used with caution in patients who may at risk of increased bleeding from trauma, surgery, or other pathological conditions. If a patient is to undergo elective surgery and an antiplatelet effect is not desired, Clopidogrel should be discontinued 7 days prior to surgery. Clopidogrel should be used with caution in patients who have lesions with a propensity to bleed (such as ulcers). Drugs that might induce such lesions such as aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) should be with caution in patients taking Clopidogrel.
Experience is limited in patients with severe hepatic disease, who may have bleeding diatheses. Clopidogrel should be administered with caution in this population. Safety and effectiveness of the drug in pediatric population has not been established. Clopidogrel should be used in pregnant and lactating mothers only when clearly needed.